

Hugo Vanderstichele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10949982/publications.pdf>

Version: 2024-02-01

89
papers

13,533
citations

44069

48
h-index

49909

87
g-index

91
all docs

91
docs citations

91
times ranked

10375
citing authors

#	ARTICLE	IF	CITATIONS
1	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582.	0.8	51
2	Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for β -synuclein measurement. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1653-1661.	2.3	2
3	First amyloid β 1-42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, 1493-1503.	0.8	42
4	Antibody-based methods for the measurement of β -synuclein concentration in human cerebrospinal fluid – method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019, 149, 126-138.	3.9	44
5	Cerebrospinal Fluid Total and Phosphorylated β -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. <i>Molecular Neurobiology</i> , 2019, 56, 3476-3483.	4.0	26
6	Ultrasensitive Detection of Plasma Amyloid- β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 775-783.	2.6	38
7	Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. <i>Journal of Neurochemistry</i> , 2019, 149, 139-157.	3.9	10
8	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 871-882.	3.7	79
9	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	3.7	13
10	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. <i>SLAS Technology</i> , 2018, 23, 188-197.	1.9	5
11	Plasma A β (Amyloid- β) Levels and Severity and Progression of Small Vessel Disease. <i>Stroke</i> , 2018, 49, 884-890.	2.0	27
12	C-Reactive Protein, Plasma Amyloid- β Levels, and Their Interaction With Magnetic Resonance Imaging Markers. <i>Stroke</i> , 2018, 49, 2692-2698.	2.0	46
13	Commutability of the certified reference materials for the standardization of β -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β -amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2058-2066.	2.3	27
14	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.8	87
15	Plasma amyloid- β levels, cerebral atrophy and risk of dementia: a population-based study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 63.	6.2	39
16	Relevance of A β 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	3.4	59
17	CSF A β 1-42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation. <i>Clinica Chimica Acta</i> , 2017, 467, 27-33.	1.1	104
18	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A β 42 /A β 40 ratio. , 2017, 13, 885-892.		52

#	ARTICLE	IF	CITATIONS
19	Accelerating drug development for Alzheimer's disease through the use of data standards. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 273-283.	3.7	10
20	Plasma Amyloid- β^2 Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 977-987.	2.6	43
21	A user's guide for β -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	3.9	54
22	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 169-183.	2.6	21
23	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, β -synuclein, and total tau in combination with A β^{42} /A β^{40} . <i>Alzheimer's Research and Therapy</i> , 2017, 9, 40.	6.2	17
24	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.8	227
25	Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. <i>Alzheimer's and Dementia</i> , 2017, 13, 701-709.	0.8	35
26	Differential role of CSF fatty acid binding protein 3, β -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 52.	6.2	101
27	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 97-106.	2.6	20
28	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 19-35.	2.6	35
29	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 55-67.	2.6	27
30	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016, 11, 65.	10.8	16
31	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 42.	6.2	14
32	CSF A β^{42} /A β^{40} and A β^{42} /A β^{38} ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165.	3.7	329
33	Assessing the commutability of reference material formats for the harmonization of amyloid- β^2 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1177-1191.	2.3	49
34	A First Tetraplex Assay for the Simultaneous Quantification of Total β -Synuclein, Tau, β -Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2016, 11, e0153564.	2.5	6
35	O4-11-06: The confidence level of established cut-off values for CSF Alzheimer's disease-specific biomarkers. , 2015, 11, P298-P298.		2
36	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791.	0.8	79

#	ARTICLE	IF	CITATIONS
37	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	7.6	109
38	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	10.1	144
39	Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 23.	6.2	3
40	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 53-61.	0.8	114
41	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.8	344
42	Validation of Assays for Measurement of Amyloid- β Peptides in Cerebrospinal Fluid and Plasma Specimens from Patients with Alzheimer's Disease Treated with Solanezumab. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 897-910.	2.6	17
43	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. <i>Clinical Chemistry</i> , 2012, 58, 787-789.	3.2	50
44	Validation of a Multiplex Assay for Simultaneous Quantification of Amyloid- β Peptide Species in Human Plasma with Utility for Measurements in Studies of Alzheimer's Disease Therapeutics. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 905-918.	2.6	29
45	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 117-131.	2.6	40
46	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 65-73.	0.8	271
47	Improved protocol for measurement of plasma β -amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. , 2012, 8, 250-260.		56
48	Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. <i>Methods</i> , 2012, 56, 484-493.	3.8	85
49	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 13-20.	2.6	94
50	Potential sources of interference on A β immunoassays in biological samples. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 39.	6.2	14
51	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β 42. <i>Biomarkers in Medicine</i> , 2012, 6, 409-417.	1.4	76
52	Analytical aspects of molecular Alzheimer's disease biomarkers. <i>Biomarkers in Medicine</i> , 2012, 6, 377-389.	1.4	26
53	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.8	354
54	Validation of ELISA Methods for Quantification of Total Tau and Phosphorylated-Tau181 in Human Cerebrospinal Fluid with Measurement in Specimens from Two Alzheimer's Disease Studies. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 531-541.	2.6	23

#	ARTICLE	IF	CITATIONS
55	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. <i>Acta Neuropathologica</i> , 2011, 121, 597-609.	7.7	256
56	Factors affecting A β plasma levels and their utility as biomarkers in ADNI. <i>Acta Neuropathologica</i> , 2011, 122, 401-13.	7.7	151
57	Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β -Amyloid 1-42, Total tau, and P-tau ₁₈₁ for Identifying Alzheimer Disease Amyloid Plaque Pathology. <i>Archives of Neurology</i> , 2011, 68, 1137.	4.5	161
58	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. <i>Archives of Neurology</i> , 2010, 67, 949.	4.5	407
59	Evaluation of plasma A β ²⁴⁰ and A β ²⁴² as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 357-367.	3.1	242
60	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010, 31, 1867-1876.	3.1	63
61	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. <i>Annals of Neurology</i> , 2009, 65, 403-413.	5.3	1,803
62	Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. <i>European Journal of Paediatric Neurology</i> , 2008, 12, 334-341.	1.6	20
63	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	3.1	94
64	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008, 29, 1143-1159.	3.1	217
65	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 255-260.	2.6	117
66	Analytical performance and clinical utility of the INNOTEST [®] PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1472-80.	2.3	145
67	Effects of Processing and Storage Conditions on Amyloid β (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice. <i>Clinical Chemistry</i> , 2005, 51, 189-195.	3.2	151
68	Amino-Truncated β -Amyloid ₄₂ Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment. <i>Clinical Chemistry</i> , 2005, 51, 1650-1660.	3.2	82
69	Differences and Similarities between Two Frequently Used Assays for Amyloid β 42 in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2005, 51, 1057-1060.	3.2	9
70	Simultaneous Measurement of β -Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology. <i>Clinical Chemistry</i> , 2005, 51, 336-345.	3.2	400
71	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2004, 61, 95.	12.3	390
72	Neurotoxicity Marker Profiles in the CSF are not Age-Dependent but Show Variation in Children Treated for Acute Lymphoblastic Leukemia. <i>Neurotoxicology</i> , 2004, 25, 471-480.	3.0	16

#	ARTICLE	IF	CITATIONS
73	Plasma Levels of β -Amyloid(1-40), β -Amyloid(1-42), and Total β -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins. <i>Archives of Neurology</i> , 2004, 61, 333.	4.5	109
74	Cerebrospinal fluid levels of total-tau, phospho-tau and $A\beta_{42}$ predicts development of Alzheimer's disease in patients with mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 47-51.	2.1	140
75	Unaltered Plasma Levels of β -Amyloid(1-40) and β -Amyloid(1-42) upon Stimulation of Human Platelets. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 93-97.	1.5	16
76	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. <i>Neuroscience Letters</i> , 2001, 297, 187-190.	2.1	401
77	Tau and $A\beta_{42}$ in Cerebrospinal Fluid from Healthy Adults 21-93 Years of Age: Establishment of Reference Values. <i>Clinical Chemistry</i> , 2001, 47, 1776-1781.	3.2	420
78	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 257-264.	1.5	102
79	Cerebrospinal fluid τ , and β -amyloid(1-42) in dementia disorders. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2005-2011.	4.6	50
80	Evaluation of CSF-tau and CSF- $A\beta_{42}$ as Diagnostic Markers for Alzheimer Disease in Clinical Practice. <i>Archives of Neurology</i> , 2001, 58, 373-9.	4.5	487
81	The discrepancy between presenilin subcellular localization and γ -secretase processing of amyloid precursor protein. <i>Journal of Cell Biology</i> , 2001, 154, 731-740.	5.2	155
82	Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke. <i>Journal of Alzheimer's Disease</i> , 2000, 2, 199-206.	2.6	183
83	Ageing Increased Amyloid Peptide and Caused Amyloid Plaques in Brain of Old APP/V717I Transgenic Mice by a Different Mechanism than Mutant Presenilin1. <i>Journal of Neuroscience</i> , 2000, 20, 6452-6458.	3.6	107
84	Prominent Cerebral Amyloid Angiopathy in Transgenic Mice Overexpressing the London Mutant of Human APP in Neurons. <i>American Journal of Pathology</i> , 2000, 157, 1283-1298.	3.8	213
85	Standardization of measurement of β -amyloid(1-42) in cerebrospinal fluid and plasma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 245-258.	3.0	286
86	Cerebrospinal Fluid β -Amyloid(1-42) in Alzheimer Disease. <i>Archives of Neurology</i> , 1999, 56, 673.	4.5	594
87	The Glu318Gly Substitution in Presenilin 1 Is Not Causally Related to Alzheimer Disease. <i>American Journal of Human Genetics</i> , 1999, 64, 290-292.	6.2	47
88	Evidence That $A\beta_{42}$ Plasma Levels in Presenilin-1 Mutation Carriers Do not Allow for Prediction of Their Clinical Phenotype. <i>Neurobiology of Disease</i> , 1999, 6, 280-287.	4.4	48
89	Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. <i>Nature</i> , 1998, 391, 387-390.	27.8	1,765